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The enzyme NADPH oxidase is regulated by phospho-
lipase D in intact neutrophils and is activated by phos-
phatidic acid (PA) plus diacylglycerol (DG) in cell-free
systems. We showed previously that cell-free NADPH
oxidase activation by these lipids involves both protein
kinase-dependent and -independent pathways. Here we
demonstrate that only the protein kinase-independent
pathway is operative in a cell-free system of purified
and recombinant NADPH oxidase components. Activa-
tion by PA 1 DG was ATP-independent and unaffected
by the protein kinase inhibitor staurosporine, indicat-
ing the lack of protein kinase involvement. Both PA and
DG were required for optimal activation to occur. The
drug R59949 reduced activation of NADPH oxidase by
either arachidonic acid or PA 1 DG, with IC50 values of
46 and 25 mM, respectively. The optimal concentration of
arachidonic acid or PA 1 DG for oxidase activation was
shifted to the right with R59949, indicating interference
of the drug with the interaction of lipid activators and
enzyme components. R59949 inhibited the lipid-induced
aggregation/sedimentation of oxidase components
p47phox and p67phox, suggesting a disruption of the lipid-
mediated assembly process. The direct effects of R59949
on NADPH oxidase activation complicate its use as a
“specific” inhibitor of DG kinase. We conclude that the
protein kinase-independent pathway of NADPH oxidase
activation by PA and DG involves direct interaction
with NADPH oxidase components. Thus, NADPH oxi-
dase proteins are functional targets for these lipid mes-
sengers in the neutrophil.
The NADPH oxidase (the respiratory burst enzyme) in phag-
ocytic cells produces superoxide (O2
.)1 by catalyzing electron
transfer from NADPH to molecular oxygen upon cell stimula-
tion (1–3). This enzyme plays important roles in host defense
against infection and in tissue damage due to inflammation
(1–5). In addition, NADPH oxidase-like enzymes are present in
a variety of other cell types, where the oxygen radicals formed
may have signaling roles (5, 6). The enzyme in phagocytes
consists of the membrane-bound heterodimeric flavocyto-
chrome b558 (gp91
phox and p22phox) and four cytosolic proteins
(p47phox, p67phox, p40phox, Rac1/2) (2–4, 7). Components must
assemble in the membrane for the enzyme to become active
(2–4, 7). The activation of NADPH oxidase is initiated by
receptor-ligand interaction and involves complex intracellular
signaling events. These include the activation of protein ki-
nases to phosphorylate cellular proteins and NADPH oxidase
components (2, 8) and the generation of various lipid second
messengers (AA by phospholipase A2 (9); DG by phospholipase
C or PA phosphohydrolase; PA by phospholipase D or DG
kinase (10, 11)). In cell-free systems, these lipids can induce
activation of the enzyme (12–17). AA exerts its effect by directly
acting on enzyme components (18–22). PA has been shown to
partially activate purified flavocytochrome b558 (23), suggest-
ing it interacts with this protein. It is not known whether DG
has any direct effect(s) on NADPH oxidase components.
Previous studies examined NADPH oxidase activation by PA
plus DG in a cell-free system consisting of membrane and
cytosolic fractions from human neutrophils (16, 17, 24). Both
lipids are required for optimal activation (16, 17), but the
individual roles of each are not clear. We showed (24) that
activation in this system is dependent on both protein kinase
activity and other undefined phosphorylation-independent
mechanisms. The protein kinase-dependent mechanism may
involve the phosphorylation of NADPH oxidase components
p47phox and p22phox by a novel PA-activated protein kinase (10,
25, 26). Alternatively, Erickson et al. (17) postulated that the
phosphorylation-dependent mechanism involved the conver-
sion of DG to PA by DG kinase. They found that the DG kinase
inhibitor R59949 blocked the formation of PA from DG as well
as the activation of NADPH oxidase by DG.
R59949 inhibits DG kinase with an IC50 value of 1.25 3 10
27
M in isolated platelet membranes and in intact platelets (27).
However, at concentrations above 1025 M, the drug has non-
specific effects on overall lipid and protein metabolism (28).
Since then, R59949 has been widely used (29, 30). Jiang et al.
showed (31) that R59949 is selective for Ca21-activated DG
kinases and that the drug interacts with the catalytic subunit
of the enzyme. These observations raise the possibility that the
effect of R59949 on cell-free NADPH oxidase activation (17) is
unrelated to inhibition of DG kinase, since high concentrations
were used, and Ca21 was not present in the activation system.
Here, we further analyzed the individual roles of PA and DG
on NADPH oxidase activation using purified and recombinant
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NADPH oxidase components. Optimal activation still required
both PA and DG, and activation was independent of ATP and
protein kinase activity. We used this system to further study
the mechanism of activation of NADPH oxidase. We found that
R59949 acts in a DG kinase-independent manner on this proc-
ess through competition between R59949 and lipids during the
activation process. This characteristic of R59949 should be
considered before it is used at higher concentrations (.10 mM)
in either in vivo or in vitro assays. These results strongly
suggest that both PA and DG interact directly with NADPH
oxidase components and that this interaction is responsible for
the protein kinase-independent mechanism of oxidase activa-
tion by these lipid second messengers.
EXPERIMENTAL PROCEDURES
Materials—Phosphatidylcholine (PC) (porcine liver, 99% pure) was
from Doosan-Serdary Research Laboratories (Englewood Cliffs, NJ),
and Type IV-S PC (soybean, 40% pure) was from Sigma. The PA used
was 1,2-dicapryl-sn-glycero-3-phosphate, and the DG used was 1-oleoyl-
2-acetyl-sn-glycerol; both were from Avanti Polar Lipids, Inc. (Alabas-
ter, AL). Lipids were freshly prepared by sonication in water (16).
Arachidonic acid was from Nu Chek Prep. Inc. (Elysian, MN), and was
prepared in 25% ethanol (16, 32). R59949 [3-[2-[4-[bis(4-fluorophenyl)
methylene]-1-piperidinyl]ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolin-
one] was from Alexis Corp. (San Diego, CA) and was dissolved in
Me2SO. N-Octyl-b-D-glucopyranoside (OG) was from Calbiochem-Nova-
biochem. SDS-polyacrylamide gel electrophoresis reagents were from
Bio-Rad. NADPH and superoxide dismutase were from Roche Molecu-
lar Chemicals. Glutathione beads, dextran T-500, and Q-Sepharose
Fast Flow were from Amersham Pharmacia Biotech. Isolymph was
from Gallard-Schlesinger Industries (Carle Place, NY). The ATP deter-
mination kit was from Molecular Probes (Eugene, OR). The p47phox and
p67phox vector-containing baculoviruses were generous gifts from
Dr. David Lambeth (Emory University, Atlanta, GA). The p47phox and
p67phox proteins were produced in Sf9 cells and partially purified on
CM-cellulose (p47phox) or Q-Sepharose Fast Flow (p67phox) (33). The
goat anti-p47phox and anti-p67phox antibodies were generous gifts from
Dr. Tom Leto (NIAID, NIH, Bethesda, MD). The Q61L active confor-
mational mutant of Rac1 (a generous gift from Dr. Tom Leto) was
produced in Escherichia coli as a glutathione S-transferase fusion pro-
tein and purified on glutathione-Sepharose beads by thrombin cleavage
(34). All other reagents were from Sigma.
Isolation of Neutrophils and Subcellular Fractions—Heparinized ve-
nous blood was obtained from healthy donors, and neutrophils were
isolated by dextran sedimentation and centrifugation through Isolymph
(35). Isolated neutrophils were treated with diisopropyl fluorophos-
phate (26), resuspended in sonication buffer (11% sucrose, 50 mM
NaxPO4, pH 7.0, 120 mM NaCl, 5 mM EGTA, 1 mM phenylmethylsulfo-
nyl fluoride (PMSF), 10 mM benzamidine, 1 mg/ml leupeptin, 1 mM
pepstatin, 1 mg/ml aprotinin), and broken by sonication (36). Sonicates
were centrifuged (200 3 g, 10 min) to remove unbroken cells and nuclei,
layered onto a 15/40% (w/v) discontinuous sucrose gradient, and cen-
trifuged (150,000 3 g, 30 min) (36). Cytosolic fractions were collected
from the top layer down to the 15% interface, and membrane fractions
were collected from the 15/40% interface. Fractions were stored at
270 °C. Protein concentration was determined using the Coomassie
Plus Protein protocol from Pierce using bovine serum albumin as a
standard.
Purification and Relipidation of Flavocytochrome b558—Human neu-
trophil membrane fractions were prepared as described (37). NaCl was
added to the suspended membranes to a final concentration of 1 M, and
membranes were centrifuged at 100,000 3 g for 30 min at 4 °C. The
pellet was resuspended by transferring to a cell homogenizer and grind-
ing until milky in 1–2 ml of solubilization buffer (10 mM HEPES, 1 mM
EDTA, 1 mM MgCl2, 40 mM OG, 100 mM KCl, 10 mM NaCl, and 2 mM
NaN3, pH 7.4, with 10 mg/ml chymostatin, 1 mM dithiothreitol (DTT), 10
mM FAD, 100 mM NADPH, and 1 mM PMSF added just before use). The
homogenate was reconstituted to its original volume in solubilization
buffer, sonicated briefly on ice using a probe-style sonicator, stirred on
ice for 1–2 h, and centrifuged at 100,000 3 g for 45 min at 4 °C. The
supernatant was diluted to a salt concentration of 75 mM with dilution
buffer (10 mM HEPES, 1 mM EGTA, 1 mM MgCl2, 40 mM OG, 2 mM
NaN3, pH 7.4, supplemented with 10 mg/ml chymostatin, 0.1 mM DTT,
10 mM FAD, 100 mM NADPH, and 1 mM PMSF just before use). The
diluted supernatant was introduced to a heparin-agarose affinity col-
umn (Sigma catalog number H0402) that had previously been rinsed
with 30 bed volumes of dilution buffer with 2 M NaCl added and
equilibrated with ;50 bed volumes of wash buffer (10 mM HEPES, 1 mM
EGTA, 1 mM MgCl2, 40 mM OG, 75 mM NaCl, 2 mM NaN3, pH 7.4,
supplemented with 10 mg/ml chymostatin, 0.1 mM DTT, 10 mM FAD, 100
mM NADPH, and 0.2 mM PMSF just before use); the flow rate was 20
ml/h. The cytochrome was eluted using a 0.075–2 M NaCl gradient in
elution buffer (50 mM NaH2PO4, 1 mM EGTA, 1 mM MgCl2, 40 mM OG,
2 mM NaN3, pH 7.4, supplemented with 10 mg/ml chymostatin, 0.1 mM
DTT, 10 mM FAD, 100 mM NADPH, and 0.2 mM PMSF just before use).
One-ml fractions were collected, and those containing flavocytochrome
b absorbance were pooled and concentrated to a final volume of 1 ml
using a 50-kDa nominal molecular mass centrifugal concentration de-
vice (Millipore). The sample was passed through a 0.2-mm pore size
syringe filter and introduced to a gel filtration column (Amersham
Pharmacia Biotech Superdex 200 HR, 10–30) maintained at 4 °C and
previously equilibrated in high performance liquid chromatography
column buffer (50 mM NaH2PO4, 1 mM EGTA, 1 mM MgCl2, 40 mM OG,
150 mM NaCl, 2 mM NaN3, pH 7.4, supplemented with 10 mg/ml chy-
mostatin, 0.1 mM DTT, 10 mM FAD, and 0.2 mM PMSF just before use).
Peak fractions containing flavocytochrome b were collected in 500-ml
aliquots, and cytochrome concentrations were determined using e414 5
130.8 mM21 cm21 (38). The preparation was greater than 90% pure
cytochrome, the major contaminant being CD11b/CD18. Glycerol was
added to each fraction to a final concentration of 20%, and fractions
were stored at 4 °C, wrapped in foil, and relipidated within 2 days. The
entire purification process, beginning at the salt wash, was completed
in 1 day.
Stored fractions were relipidated as described (19, 23), with modifi-
cations. Briefly, PC (soybean, Type IV-S, 7 mg/ml), was prepared by
sonication in buffer A (50 mM Na3PO4, pH 7.0, 1 mM EGTA, 1 mM
MgCl2, 50 mM Na3N, 20% glycerol, 40 mM OG, 0.05 mM DTT, 1 mM FAD).
The lipid solution (0.7 mg/ml final) was added to the purified flavocy-
tochrome b558 (600 ml, 0.85–1.2 mM). The mixture was kept on ice for 20
min, diluted 6-fold with phosphate buffer (50 mM Na3PO4, pH 7.0, 1 mM
EGTA, 1 mM MgCl2) and stored at 270 °C. The flavocytochrome b558
concentration in the relipidated mixture was determined spectrophoto-
metrically from the reduced minus oxidized spectrum using e428 nm5106
mM21 cm21 (39).
NADPH Oxidase Activation and Assay—Mixtures containing 50 mM
NaxPO4 buffer, pH 7.0, 100 mM cytochrome c, 10 mM FAD, 1 mM EGTA,
5 mM MgCl2, zero or 12 mM ATP, zero or 0.16 mg/ml superoxide dis-
mutase, 0.5 mg of membrane protein (0.6 pmol of flavocytochrome b558)
(semi-recombinant system), or 2 pmol of relipidated flavocytochrome
b558 (purified-recombinant system) plus 40 pmol p47
phox, 15 pmol
p67phox, and 60 pmol Q61L Rac1 (hereafter referred to as Rac1) were
incubated with various concentrations of PA, DG, or PA plus DG for 90
min or with AA for 30 min in a final volume of 0.12 ml. For Figs. 4–6,
R59949 or 0.1% Me2SO (solvent control) was added into the reaction
mixture before the addition of lipid activators. After the desired incu-
bation time, 200 mM NADPH was added, and the reactions were stopped
at 2 min by 1% (v/v) Triton X-100 (16, 24). In some experiments (de-
scribed under “Results”), R59949 or 0.1% Me2SO4 (solvent control) was
added with the NADPH at the end of the incubation. The O2
. production
was determined by measuring the absorbance of cytochrome c at 550
nm using a Thermomax® kinetic microplate reader (Molecular Devices
Corp., Menlo Park, CA) and correcting for the absorbance of samples
containing superoxide dismutase. Activity was linear over the 2-min
assay period and was expressed as mol of O2
./min/mol of flavocyto-
chrome b558 using an extinction coefficient of 21 mM
21 cm21 for cyto-
chrome c (40). IC50 values were determined in SigmaPlot (Jandel Sci-
entific Software, San Rafael, CA) by fitting the data to the hyperbolic
decay equation (competitive inhibition model) (41), activity 5 max
activity 3 IC50/[R59949]1 IC50. EC50 values were determined in Sig-
maPlot using the single rectangular three-parameter nonlinear regres-
sion model.
ATP Determination—The ATP concentrations present in membrane
fractions and stock solutions of recombinant p47phox, p67phox, and Rac1
were determined by using the ATP determination kit from Molecular
Probes (42). Samples were boiled for 5 min before analysis. Lumines-
cence was read on a Turner TD 20e Luminometer (Sunnyvale, CA), and
values were calculated based on an ATP standard curve.
Sedimentation of p47phox and p67phox by PA 1 DG—Mixtures (0.12
ml) containing 50 mM NaxPO4 buffer, pH 7.0, 10 mM FAD, 1 mM EGTA,
5 mM MgCl2, zero or 0.5 mg of membrane protein (0.6 pmol of flavocy-
tochrome b558), 40 pmol of p47
phox, 15 pmol of p67phox, and 60 pmol of
Q61L Rac1 were incubated with 20 mM PC or 10 mM PA 1 10 mM DG for
90 min in the presence or absence of 50 mM R59949. Ten reaction
mixtures for each condition were mixed (1.2 ml) and layered on a
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15/50% (w/v) (1 ml/0.5 ml) discontinuous sucrose gradient and centri-
fuged in a SW55 rotor (Beckman Instruments) at 150,000 3 g for 30 min
at room temperature (43). Soluble fractions were collected from the top
of the gradient (0.9 ml); the pellet fractions were collected from the
15/50% interface plus the 50% fraction (0.75 ml). Proteins from 140 ml
of each soluble and pellet fraction were separated by 10% SDS-poly-
acrylamide gel electrophoresis (44), transferred to nitrocellulose (45),
and analyzed by Western blot with a 1:500 dilution of a mixture of
p47phox and p67phox antibodies. Blots were developed using SuperSig-
nalTM enhanced chemiluminescence reagent (Pierce) and analyzed by
densitometry (PDI, Huntington Station, NY). The percentage of each
protein in the pellet fraction was calculated using the sum of the soluble
and pellet fractions as 100%. The pmol amounts of each protein in the
pellet fraction, after treatment with PA 1 DG, were estimated using the
pmol added to the reaction mixture (calculated after correcting for the
purity of the added protein) as 100%.
Membrane NADPH Oxidase Assay—Pellet fractions containing neu-
trophil membrane from the sedimentation assay were analyzed for
their NADPH oxidase activity, as described previously (46). 80 ml of
each sample was mixed and incubated for 5 min at room temperature
with 20 mM KxPO4, pH 7.0, 1 mM EGTA, 7.6 mM MgCl2, 10 mM FAD, 75
mM cytochrome c, and 0.16 mM SDS in a final volume of 220 ml. The
mixture was divided into two cuvettes, one containing superoxide dis-
mutase at a final concentration of 0.24 mg/ml. The reaction was started
by the addition of NADPH (final concentration, 0.2 mM) to both cu-
vettes, and absorbance changes were monitored continuously at 550 nm
by a UV-2401PC Shimadzu spectrophotometer (Columbia, MD). O2
.
production was calculated using the linear slopes and an extinction
coefficient for cytochrome c of 21 mM21 cm21 (40). Activity was ex-
pressed as nmol of O2
./min/ml of pellet fraction, since the amount of
protein and flavocytochrome b558 present in the fractions were too low
to measure.
RESULTS
Characteristics of NADPH Oxidase Activation by PA 1 DG in
a Cell-free System Using Purified and Recombinant Oxidase
Components—Previous studies (16, 17, 24) examined cell-free
NADPH oxidase activation by PA 1 DG using mixtures of
membrane and cytosolic fractions from human neutrophils.
Results indicated that oxidase activation required both PA and
DG for optimal activity and involved both phosphorylation-de-
pendent and -independent mechanisms (17, 24). Our previous
data (24–26) suggested that the phosphorylation-dependent
mechanism involved one or more cytosolic protein kinases.
Therefore, we hypothesized that the substitution of recombi-
nant NADPH oxidase components for the neutrophil cytosolic
fraction would eliminate the phosphorylation-dependent acti-
vation pathway. To test this, we examined the ability of PA 1
DG to activate NADPH oxidase in a “semi-recombinant” cell-
free system consisting of the recombinant proteins p47phox,
p67phox, and Rac1 mixed with neutrophil membrane fractions.
As shown in Fig. 1A, PA 1 DG induced NADPH oxidase acti-
vation in the semi-recombinant system. To test whether a
protein kinase was involved in NADPH oxidase activation in
this system, we examined the effect of a potent, nonselective
protein kinase inhibitor, staurosporine (47). Staurosporine re-
duced NADPH oxidase activation by about 50% when neutro-
phil cytosol was used as the source of cytosolic oxidase compo-
nents (Fig. 1A, left panel). In contrast, staurosporine had no
effect on NADPH oxidase activation by PA 1 DG in the semi-
recombinant system (Fig. 1A, right panel).
To further address whether activation by PA 1 DG in the
semi-recombinant system was phosphorylation-independent,
we tested the effect of ATP. The endogenous ATP concentration
in our reaction mixtures of membrane and recombinant oxidase
proteins was determined to be 1 6 0.9 nM (mean 6 S.E., n 5 3),
which is too low to support lipid or protein phosphorylation
reactions. We performed concentration curves with PA 1 DG in
the presence or absence of 12 mM added ATP (Fig. 1B). The
curves were virtually superimposable, indicating that ATP had
no effect on the level of activity or the EC50 for the lipids. Taken
together, these data indicate that activation of NADPH oxidase
by PA 1 DG in the semi-recombinant system is phosphoryla-
tion- and protein kinase-independent.
We next addressed whether both PA and DG were required
for activation to occur in the semi-recombinant system. As
shown in Fig. 2A, oxidase activity was negligible with DG alone
and was present at only low levels with PA alone. In contrast,
when both lipids were added, substantial levels of oxidase
activity were detected. AA induced similar levels of activation
as PA 1 DG. Both PA and DG could have direct activating
effects on one or more oxidase components. However, the neu-
trophil membrane fraction present in the semi-recombinant
system might have other targets for one or both of these lipids,
which could influence oxidase activation. Therefore, we tested
the effect of PA and DG on oxidase activation when purified,
relipidated (with soybean PC) flavocytochrome b558 replaced
neutrophil membrane. Levels of oxidase activation were lower
compared with the semi-recombinant system. As shown in Fig.
2B, DG alone was ineffective in this system, whereas PA
FIG. 1. Activation of NADPH oxidase by PA 1 DG in a semi-
recombinant cell-free system is protein kinase-independent. A,
effect of staurosporine. Reaction mixtures contained the following. Left
panel, 0.25 mg of membrane protein (0.3 pmol of flavocytochrome b558)
and 12.5 mg of cytosolic protein and were incubated with H2O or 100 mM
PA 1 100 mM DG; right panel, 0.5 mg of membrane protein (0.6 pmol of
flavocytochrome b558), 40 pmol of p47
phox, 15 pmol of p67phox, and 60
pmol of Rac1 and were incubated with 30 mM PC or 30 mM PA 1 10 mM
DG. Assays were performed in the presence of 12 mM added ATP and in
the presence of either Me2SO (DMSO, light gray bars) or 100 nM
staurosporine (dark gray bars). NADPH oxidase activity was measured
as described under “Experimental Procedures” and expressed as mol of
O2
./min/mol of flavocytochrome b558. The data shown are mean 6 S.E. of
three (left panel) or seven (right panel) experiments. B, effect of ATP.
Reaction mixtures contained 0.5 mg of membrane protein (0.6 pmol of
flavocytochrome b558), 40 pmol of p47
phox, 15 pmol of p67phox, and 60
pmol of Rac1 and were incubated with various amounts of PA 1 DG in
the presence (f) or absence (M) of 12 mM added ATP. PA and DG were
present at equal concentrations, each representing half of the total
value shown at any given concentration. NADPH oxidase activity was
measured as described under “Experimental Procedures” and expressed
as mol of O2
./min/mol of flavocytochrome b558. The data shown are
mean 6 S.E. of three experiments.
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showed slight activation of the enzyme. However the combina-
tion of the two lipids induced a greater than additive response,
similar to that observed in the semi-recombinant system. AA
also could activate NADPH oxidase in this purified-recombi-
nant system, similar to observations by others (18, 19). These
results strongly suggest that one or more NADPH oxidase
components is a direct target(s) of PA and DG for the activation
of the enzyme.
As shown in Fig. 3, the activation of NADPH oxidase by PA
1 DG in both the semi-recombinant and purified-recombinant
cell-free systems reached a maximum by 30 min and did not
decline for up to 90 min. The rate of activation was faster in the
purified-recombinant system, since ;40% of maximum activity
was achieved without preincubation (Fig. 3B) compared with
;25% of maximum in the semi-recombinant system at zero
time (Fig. 3A). The zero time point includes a 2-min incubation
for measurement of NADPH oxidase activity, indicating that
the rate of activation in the first 2 min is almost twice as fast
in the purified-recombinant cell-free system.
Effect of R59949 on the Activation of NADPH Oxidase in the
Semi-recombinant Cell-free System—The above data indicated
that oxidase activation in the semi-recombinant system was
independent of phosphorylation reactions and suggested that
both PA and DG were required for the activation process.
Previously, Erickson et al. (17) used the DG kinase inhibitor
R59949 to suggest that a phosphorylation-dependent mecha-
nism of oxidase activation by PA 1 DG involved the conversion
of DG to PA by DG kinase. Since our results suggest that DG
has direct effects on NADPH oxidase component(s), we hypoth-
esized that R59949 might exert its inhibitory effect in a DG
kinase-independent way. Thus, we studied the effect of R59949
on oxidase activation in the semi-recombinant system, where
phosphorylation-dependent reactions are not involved.
NADPH oxidase activation was examined in the presence of
various concentrations of R59949 using either AA or PA 1 DG
as lipid activators. Assays were performed in the presence of 12
mM ATP to maximize the ability of any DG kinase present in the
membrane to convert DG to PA. As shown in Fig. 4A, R59949
had no inhibitory effect on oxidase activation until the concen-
tration was above 10 mM, and inhibition was nearly complete at
100 mM. The IC50 for inhibition by R59949 was 25 mM with PA
1 DG and 46 mM with AA. R59949 (50 mM) was not inhibitory
when added after the preincubation with lipids (PA 1 DG:
2608 6 260 versus PA 1 DG 1 R59949: 2521 6 260; AA: 3130 6
434 versus AA 1 R59949: 4196 6 262 mol O2
./min/mol of flavo-
cytochrome b558, mean 6 S.E., n 5 3). AA is documented to
induce NADPH oxidase activation through direct interaction
with NADPH oxidase components (18, 19). Our results in Figs.
1–3 indicate that PA and DG do the same in the semi-recom-
binant cell-free system. Therefore, these data suggest that
R59949 directly interferes with the ability of lipids to induce
activation of NADPH oxidase.
R59949 Shifts to the Right the Optimal Concentration of
FIG. 2. Both PA and DG are required for optimal NADPH oxi-
dase activation in the semi-recombinant and purified-recombi-
nant cell-free systems. A, semi-recombinant system. Reaction mix-
tures contained 0.5 mg of membrane protein (0.6 pmol of
flavocytochrome b558), 40 pmol of p47
phox, 15pmol of p67phox, and 60
pmol of Rac1 and were incubated with 30 mM PC, 10 mM PA, 10 mM DG,
or PA 1 DG (10 mM each) for 90 min or ethanol (Eth) or 25 mM AA for 30
min. ATP (12 mM) was present in all reaction mixtures except those
containing AA. NADPH oxidase activity was measured as described
under “Experimental Procedures.” Data shown are the mean 6 S.E. of
three experiments. B, purified-recombinant system. Reaction mixtures
were as above, except that 2 pmol of purified, relipidated flavocyto-
chrome b558 was substituted for the membrane protein. Mixtures were
incubated with either H2O, 30 mM PA, 30 mM DG, or 30 mM PA 1 30 mM
DG for 90 min or with ethanol (Eth) or 10 mM AA for 30 min. NADPH
oxidase activity was measured as described under “Experimental Pro-
cedures.” Data shown are mean 6 S.E. (n 5 3).
FIG. 3. Time-dependent activation of NADPH oxidase by PA 1
DG in semi-recombinant and purified-recombinant cell-free sys-
tems. A, reaction mixtures as in Fig. 2A were incubated with 30 mM PA
1 30 mM DG (f) or H2O (l ) for 0–90 min. B, reaction mixtures as in Fig.
2B were incubated with 30 mM PA 1 30 mM DG (f) or H2O (l ) for 0–90
min. ATP was omitted from all reaction mixtures. NADPH oxidase
activity was measured as described under “Experimental Procedures.”
Activity is expressed as mol of O2
./min/mol of flavocytochrome b558.
Values with PA 1 DG are the mean 6 S.E. of three experiments (A) and
the average of two closely agreeing experiments (B). H2O control values
are the average of two experiments.
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Lipid Activators for the Activation of NADPH Oxidase in the
Semi-recombinant Cell-free System—To address the mecha-
nism of inhibition by R59949, we further characterized the
effect of R59949 on the concentration of AA (0–70 mM) needed
to induce NADPH oxidase activation (Fig. 4B). The presence of
50 mM R59949 shifted the optimal concentration of AA to the
right, from 15–25 to 40–50 mM AA, and slightly reduced the
maximal level of activation. These data indicate that inhibition
by R59949 of NADPH oxidase activation is likely due to com-
petition with AA for binding to and/or interaction with compo-
nents of the enzyme.
Next we addressed whether R59949 might exert a similar
effect on the amount of PA 1 DG needed for NADPH oxidase
activation. As observed with AA, 50 mM R59949 shifted the
optimal concentration of PA plus DG to the right (Fig. 5A).
R59949 increased the EC50 of PA plus DG from 17 6 7 to 72 6
22 mM (mean 6 S.E., n 5 3). We next asked whether R59949
exerted its effect on both PA and DG or on just one of these
lipids. The concentration of DG (Fig. 5B) or PA (Fig. 5C) was
varied, keeping the other lipid concentration at 10 mM. R59949
(50 mM) shifted the optimal concentration of DG to the right,
increasing the EC50 of DG from 3 6 2 to 24 6 15 mM (mean 6
S.E., n 5 3). The drug also slightly shifted the optimal concen-
tration of PA, and it also decreased the maximal NADPH
oxidase activation under these conditions. Taken together,
these results indicate that the effect of R59949 on PA 1 DG-
mediated oxidase activation is similar to that in the AA-acti-
vated system, with a shift to the right in the lipid concentration
required for optimal NADPH oxidase activation. Furthermore,
increasing the concentration of DG was better able to overcome
the inhibitory effect of the drug compared with PA. These data
suggest that R59949 is acting in a competitive manner with the
lipid activators, with selectivity for DG over PA.
R59949 Inhibits NADPH Oxidase Activation in the Purified-
recombinant Cell-free System—We tested whether R59949
would have similar inhibitory effects on NADPH oxidase acti-
vation in the purified-recombinant cell-free system. R59949
was slightly less effective in this series of studies, inhibiting
NADPH oxidase activation by PA 1 DG in the semi-recombi-
nant system by 45% at 100 mM (30 mM PA 1 30 mM DG, data not
shown). As illustrated in Fig. 6A for the purified-recombinant
FIG. 4. R59949 inhibits the activation of NADPH oxidase in the
semi-recombinant cell-free system. A, inhibition by R59949 is con-
centration-dependent. Reaction mixtures as in Fig. 2A were incubated
with 15 mM AA for 30 min (), 10 mM PA 1 10 mM DG for 90 min (f), or
H2O (l ) in the presence of 0–100 mM R59949. 12 mM ATP was present
in the PA 1 DG-activated system. B, R59949 shifts the AA concentra-
tion curve to the right. Reaction mixtures as in Fig. 2A were incubated
with 0–70 mM AA for 30 min in the presence (M) or absence (f) of 50 mM
R59949. For both panels, NADPH oxidase activity was measured as
described under “Experimental Procedures” and expressed as mol of
O2
./min/mol of flavocytochrome b558. Values with lipid activators are the
mean 6 S.E. of three experiments. Water controls are the average of
two experiments. DMSO, Me2SO.
FIG. 5. R59949 shifts the concentration curves of PA and DG
for NADPH oxidase activation to the right in the semi-recombi-
nant cell-free system. A, varying PA 1 DG. Reaction mixtures as in
Fig. 2A were incubated with various amounts of PA 1 DG in the
presence (M) or absence (f) of 50 mM R59949. PA and DG were present
at equal concentrations, each representing half of the total value shown
at any given concentration. B, varying DG. Reaction mixtures as in
panel A were incubated with 10 mM PA plus 0–300 mM DG. C, varying
PA. Reaction mixtures as in panel A were incubated with 10 mM DG plus
0–300 mM PA. NADPH oxidase activity was measured as described
under “Experimental Procedures” and expressed as mol of O2
./min/mol
of flavocytochrome b558. Values shown are the mean 6 S.E. of three
experiments. DMSO, Me2SO.
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cell-free system, 100 mM R59949 reduced NADPH oxidase ac-
tivation induced by either AA or PA 1 DG by 66 and 40%,
respectively. We also examined whether R59949 was competi-
tive with PA 1 DG in this cell-free system. As shown in Fig. 6B,
the presence of R59949 during NADPH oxidase activation
shifted the optimal concentration for the lipid activators to the
right. These data indicate that the mechanism of inhibition of
NADPH oxidase activation by R59949 is the same when only
NADPH oxidase components are present. Thus, the drug must
directly interfere with the ability of lipid activators to interact
with NADPH oxidase components.
R59949 Inhibits the Lipid-induced Sedimentation of Recom-
binant p47phox and p67phox—To further support the direct in-
terference of R59949 with lipid activators, we tested the effect
of the drug on the ability of PA 1 DG to induce aggregation and
sedimentation of cytosolic NADPH oxidase components. Previ-
ously, AA was shown to induce the presumed aggregation of
p47phox and p67phox in either the presence or absence of neu-
trophil membrane fractions, resulting in the sedimentation of
these proteins during high speed centrifugation (48). In the
presence of neutrophil membrane, this process aids in the
assembly of the active NADPH oxidase enzyme. Here, we de-
termined whether PA 1 DG induced a similar effect and
whether R59949 interfered with the aggregation/sedimenta-
tion process. Recombinant oxidase proteins were incubated
with or without neutrophil membrane fractions in the presence
or absence of lipid activators and/or 50 mM R59949, followed by
separation of pellet and soluble fractions over a discontinuous
sucrose gradient. PA 1 DG induced the appearance of both
p47phox and p67phox in the recovered pellet fraction either in the
presence or absence of neutrophil membrane (Fig. 7A). This
indicates that PA 1 DG, like AA (48), induces presumed ag-
gregation of these soluble proteins. The presence of 50 mM
R59949 inhibited the sedimentation of p47phox and p67phox
(Fig. 7A). The sedimentation of p47phox appeared to be more
sensitive to R59949, since the drug inhibited the appearance in
the pellet fraction of 98 6 2% of p47phox compared with 57 6 2%
of p67phox (Fig. 7B). Parallel to the inhibition of p47phox and
p67phox sedimentation, R59949 also markedly reduced the level
of NADPH oxidase activity appearing in the pellet fractions
containing neutrophil membrane (Fig. 7B). These results sug-
gest that R59949 interferes with the ability of lipid activators
to bind to one or more soluble NADPH oxidase components and
FIG. 6. R59949 inhibits activation of NADPH oxidase in the
purified-recombinant system. A, inhibition by R59949. Reaction
mixtures containing purified, relipidated flavocytochrome b558 and re-
combinant cytosolic oxidase components as in Fig. 2B were incubated
with ethanol (Eth) or 10 mM AA or with H2O or 30 mM PA 1 30 mM DG
in the presence (white bars) or absence (black bars) of 100 mM R59949.
DMSO, Me2SO. B, varying PA 1 DG. Reaction mixtures as in Fig. 2B
were incubated with various amounts of PA 1 DG in the presence (M)
or absence (f) of 100 mM R59949. PA and DG were present at equal
concentrations, each representing half of the total value shown at any
given concentration. Data represent the average of two closely agreeing
experiments.
FIG. 7. R59949 inhibits the aggregation/sedimentation of
p47phox and p67phox induced by PA 1 DG. Reaction mixtures con-
taining zero or 0.5 mg of membrane protein (0.6 pmol flavocytochrome
b558), 40 pmol of p47
phox, 15 pmol of p67phox, and 60 pmol of Rac1 were
incubated with 20 mM PC (no activator control) or 10 mM PA 1 10 mM DG
for 90 min in the presence or absence of 50 mM R59949. Ten reaction
mixtures were combined, and pellet and soluble fractions were sepa-
rated as described under “Experimental Procedures.” NADPH oxidase
activity in the pellet fractions containing neutrophil membrane was
measured as described under “Experimental Procedures.” Proteins
from the soluble and pellet fractions were separated on a 10% polyacryl-
amide gel, transferred to nitrocellulose, and analyzed by Western blot
for p47phox and p67phox. Panel A, shown is a representative Western blot
of pellet fractions. Panel B, left side, Western blots of recovered pellet
and soluble fractions were analyzed by densitometry. The distributions
of p47phox and p67phox were determined, and the amount (pmol) of each
protein present in the pellet fraction was calculated as described under
“Experimental Procedures.” Right side, NADPH oxidase activity was
expressed as nmol of O2
./min/ml of pellet fraction. Values shown in panel
B are mean 6 S.E. of three experiments. DMSO, Me2SO.
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induce the aggregation process, which might be an important
step for transporting p47phox and p67phox to the membrane
components in cell-free assays (48).
DISCUSSION
Here, we provide evidence that the second messenger lipids
PA and DG interact directly with components of NADPH oxi-
dase to induce assembly and activation of the enzyme. This
evidence includes the following. 1) NADPH oxidase activation
by PA plus DG in the semi-recombinant cell-free system was
ATP-independent and insensitive to the nonselective protein
kinase inhibitor staurosporine, indicating a phosphorylation-
independent mechanism; 2) PA 1 DG induced NADPH oxidase
activation when only oxidase components were present (the
purified-recombinant system); 3) PA and DG were both re-
quired for optimal activation, suggesting that each lipid may
have one or more oxidase protein targets; and 4) the drug
R59949 competitively inhibited the interaction of PA and DG
with oxidase components and prevented the assembly of
p47phox and p67phox with flavocytochrome b558.
Previously (16, 24), using mixtures of membrane and cyto-
solic fractions from human neutrophils, we found that NADPH
oxidase activation by PA 1 DG involved both protein kinase-
dependent and -independent pathways. A novel cytosolic PA-
activated protein kinase capable of phosphorylating two
NADPH oxidase components (p47phox and p22phox) was impli-
cated as responsible for the phosphorylation-dependent path-
way (10, 24–26). In addition, Erickson et al. (17) suggested that
DG kinase contributes to a phosphorylation-dependent path-
way in mixtures of membrane and cytosolic fractions. These
pathways are clearly not operative in the semi-recombinant
cell-free system, where recombinant cytosolic oxidase compo-
nents replace neutrophil cytosol.
Based on the results reported here, it is evident that the
phosphorylation-independent mechanism of NADPH oxidase
activation by PA 1 DG involves direct interaction between the
lipids and oxidase components. This direct mechanism is likely
analogous to that used by AA, since the drug R59949 caused a
similar shift to the right in the concentration curves of either
AA or PA 1 DG. AA has been shown to directly induce confor-
mational changes in both flavocytochrome b558 and p47
phox
(20–22), resulting in the SH3 domain-mediated binding of
p47phox with the p22phox subunit of the flavocytochrome (49).
PA has been shown to induce partial activation of purified
flavocytochrome b558 in the absence of cytosolic components
(23). The inhibition of the aggregation/sedimentation of p47phox
and p67phox by R59949 implies that the lipids bind to one or
both of these components. A likely target for lipid binding is
p47phox, since a change in conformation of p47phox appears to
initiate the translocation/assembly process (49–51). Indeed, we
have shown in a separate study2 that PA selectively binds to
p47phox. DG can enhance the binding of PA to the enzyme
CTP:phosphocholine cytidylyltransferase through a proposed
mechanism involving effects of DG on the clustering of PA
molecules in the lipid bilayer (52). The synergy between PA and
DG for NADPH oxidase activation could involve a similar
mechanism. Studies to address these issues are under way.
Our results also clearly show that the DG kinase inhibitor
R59949 directly interferes with the ability of lipids to activate
NADPH oxidase. Because of its lipophilic nature, R59949 may
exert its effect by interaction with the lipids, preventing their
binding to NADPH oxidase components. Alternatively, R59949
may compete for the lipid binding site(s) on oxidase proteins.
Binding sites on DG kinase or other proteins for R59949 have
not been identified. It is possible that R59949 competes with
DG for binding to the active site of certain DG kinase isoforms;
however, the catalytic binding site for DG is not known (53, 54),
and kinetic studies to address this possibility have not been
published. Our results show that increasing the concentration
of DG was more effective than increasing the concentration of
PA at overcoming the inhibition by the drug. Increasing the
concentration of AA could also overcome the effect of the drug.
This suggests that, in the oxidase system, R59949 is primarily
competitive with DG or AA.
The direct inhibitory effect on NADPH oxidase activation by
R59949 complicates interpretation of previous results (17) us-
ing this inhibitor to implicate DG kinase in cell-free NADPH
oxidase activation. Erickson et al. (17) showed that R59949
inhibited the conversion of DG to PA and also blocked the
ability of DG alone to activate NADPH oxidase. Our results
suggest that the inhibition of NADPH oxidase by R59949 in
those studies could be due to competition with lipids for oxidase
activation. However, since in our hands DG alone cannot acti-
vate NADPH oxidase, it is likely that the conversion of some of
the added DG to PA by DG kinase was involved in the activa-
tion observed by Erickson et al. (17). DG kinase may play a
regulatory role in intact neutrophils, since a number of studies
(55–57) show that DG kinase inhibitors enhance O2
. release
during agonist stimulation. These studies used drug concentra-
tions too low to have direct effects on lipid-mediated oxidase
activation. However, caution should be used when interpreting
the effects of R59949 on intact cell functions when concentra-
tions above 10–20 mM are used. NADPH oxidase-like enzymes
are now being found in a variety of cell types, where the
resulting O2
. and H2O2 may be involved in signaling pathways
(5, 6). Thus, the direct inhibition of NAD(P)H oxidase activa-
tion also may confound the use of R59949 to implicate a role for
DG kinase in functional responses in cell types other than
neutrophils.
Activation of NADPH oxidase in intact neutrophils is com-
plexly regulated and incompletely understood. A wealth of data
(reviewed in Refs. 2 and 10)) implicates the activation of pro-
tein kinases and phospholipases, particularly phospholipase D
and phospholipase A2, but how these signaling pathways con-
verge on NADPH oxidase activation is unclear. The phospho-
lipase-generated lipid messengers could activate protein kinase
C or other protein kinases (58–62), contributing to the phos-
phorylation of NADPH oxidase components. Phosphorylation
of at least one oxidase component, p47phox, is required for
oxidase activation by the nonphysiological agonist phorbol my-
ristate acetate, which activates protein kinase C isoforms (2, 8).
Phosphorylation of p47phox by protein kinase C can disrupt the
“closed conformation” of the protein, allowing it to initiate
NADPH oxidase assembly (50, 51). However, the phosphoryla-
tion-dependent mechanisms used by physiological agonists
have not been elucidated with any certainty. Shiose and Sumi-
moto (49) recently demonstrated that AA can synergize with
phosphorylation of p47phox to activate NADPH oxidase. This is
an attractive model that may help to explain the complex
regulation of oxidase activation in intact cells by physiological
agonists. In addition, we recently showed (63) that phospho-
lipase D-dependent pathways are involved in the phosphoryl-
ation of p22phox in intact cells induced by physiological ago-
nists. The use of the semi-recombinant and purified-
recombinant cell-free activation systems described here should
allow careful dissection of the functional effects of phosphoryl-
ation (by added protein kinases) and lipids on NADPH oxidase
components during the activation of the enzyme by PA and DG.
Mechanisms identified in cell-free systems would then need to
2 W.-X. Zhang, J. B. Nixon, T. L. Leto, and L. C. McPhail, manuscript
in preparation.
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be studied in intact cells to determine their physiological
relevance.
In conclusion, we have identified a protein kinase-independ-
ent pathway for NADPH oxidase activation by the lipid second
messengers PA and DG. The pathway clearly involves direct
interaction of the lipids with NADPH oxidase components.
Thus, PA and DG have multiple potential protein targets in
human neutrophils, including a novel PA-activated protein
kinase (10, 25), protein kinase C isoforms (58, 59), and now,
NADPH oxidase proteins. Interaction of PA and DG with all of
these proteins may contribute to the regulation of NADPH
oxidase in neutrophils and other cell types.
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